In a small single-arm, open-label trial in Portugal, dolutegravir + two NRTIs proved effective and safe for managing HIV-2 infection. Data are sparse regarding treatment of HIV-2 infection with contemporary ART regimens; moreover, HIV-2 exhibits intrinsic resistance to NNRTIs. Further complicating the management of HIV-2 infection is the fact that plasma HIV-2 RNA levels, when […]

We are sharing a statement from a community and civil society leaders, advocates and activists meeting on long-acting drugs for the prevention and treatment of HIV which took place in Nairobi in April 2023.In this statement, the community demands rapid action from Gilead to make Lenacapavir accessible in low and middle-income countries without further delay! […]

Greetings from Afrocab, SMART4TB is a US$200 million investment from USAID to tackle tuberculosis (TB) through research and its translation to policy and practice. The SMART4TB project is led by Johns Hopkins University and an international consortium of research partners and civil society organizations. SMART4TB will run through 2027 and will support research across five […]

In April 2023, the CAB hosted a meeting on long-acting technologies and introduction pathways. Presentations, discussions, and panel sessions featured CAB members, Ministry of Health officials, and supplier and industry representatives across two days. The sessions covered key focal areas across the product introduction pathway to inform a third and final day of work-planning and advocacy […]

On behalf of community stakeholders, Afrocab Treatment Access Partnership shared an open letter with the WHO as a follow-up to a community and advocates sign-on letter released on 3rd December 2022.  The statement called on WHO and others to accelerate access to DRV/r in the second line of HIV treatment. The community notes that since […]

In December 2021, HIV advocates from around the world demanded access to an optimal second-line medicine called darunavir/ritonavir (DRV/r), which has been used in high-income countries for over 15 years but only just recently became available outside of wealthy nations. Few countries, primarily Nigeria and Zambia, have begun to use DRV/r, but widespread access and […]

Please find our World AIDS Day Statement as we enhance our advocacy towards access to injectable CAB-LA for HIV prevention in our region and beyond!

A Special Edition of the CAB-LA newsletter: You will find the Milestones for CAB-LA Access and Progress Achieved through Community Advocacy- Where are we now and how did we get here? We hope you enjoy reading!

Please see the latest CAB-LA newsletter, which we hope you enjoy reading.You will also find a recap and key status updates on where are we now with CAB-LA.

Please see the latest CAB-LA newsletter, which we hope you find informative.